CD Markers

Home Chapter Home Jobs Conferences Fellowships Books

CD Markers

CD2

Reviewers: Nat Pernick, M.D., (see Reviewers page)
Revised: 30 November 2010, last major update November 2010
Copyright: (c) 2002-2010, PathologyOutlines.com, Inc.

General
=========================================================================

● Early T cell marker
● Gene is at 1p13.1; protein is member of immunoglobulin superfamily

General
=========================================================================

● Also called E rosette receptor, because CD2 antibodies inhibit formation of rosettes with sheep erythrocytes; LFA2 (leukocyte function antigen), T11

Physiology
=========================================================================

(a) Binds CD58 (LFA3) on antigen-presenting cells, which enables T cells to respond to lower concentrations of antigen (J Exp Med 1999;190:1383)
(b) Induces costimulatory signals in T cells
(c) Induces T cell cytokine production
(d) Mediates adhesion between T cells and antigen presenting cells
(e) Regulates T and NK-mediated cytolysis
(f) Inhibits apoptosis of activated peripheral T cells
(g) Regulates T cell anergy

Uses by pathologists
=========================================================================

● Membranous staining
● T cell marker (although CD3 is more common)
● Marker of systemic mastocytosis

Clinical features
=========================================================================

● Siplizumab, an anti-CD2 monoclonal antibody, is being studied to treat plaque psoriasis (Int J Dermatol 2010;49:818)
● Abnormal levels of CD2 expression by flow cytometry are frequently observed in mature T-cell malignancies, but clinical significance is unclear because of variability of CD2 expression in normal T cells (Cytometry B Clin Cytom 2010;78:169)

Micro images
=========================================================================

Lymph node-T cell lymphoma

Positive staining (normal)
=========================================================================

● Thymocytes (95%), mature peripheral T cells (almost all), NK cells (80-90%), mast cells
● Variable thymic B cells (50%), Langerhans cells

Positive staining (disease)
=========================================================================

● T-ALL, other T cell lymphoma/leukemia, acute promyelocytic leukemia-microgranular variant / FAB M3v (Leukemia 1995;9:1461), AML with pseudo-Chèdiak-Higashi anomaly (Am J Clin Pathol 2006;125:791), indolent systemic mastocytosis (Hum Path 2001;32:545), thymoma (lymphocyte predominant)
● Variable acute myeloid lymphoma-M0
● Rare: pyothorax associated B cell lymphoma (Am J Surg Pathol 2002;26:724) or other non-Hodgkin B cell lymphomas, Reed-Sternberg/Hodgkin’s cells (Mod Path 2005;18:1542)), myeloma (Mod Path 1990;3:302), myeloid leukemia

Negative staining
=========================================================================

● B cells, basophils, nonhematopoietic neoplasms (Am J Clin Pathol 2003;120:64), mast cells in non-mastocytosis disorders

Additional references
=========================================================================

● MIM xxxxxx

End of CD Markers > CD2

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).